Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006

Sutro Biopharma, Inc. has announced that the first patient has been dosed in its Phase 1 clinical trial for STRO-006, a next-generation antibody-drug conjugate targeting integrin β6 (ITGB6) in solid tumors. The drug features a drug-to-antibody ratio of 8 (DAR8) and is designed for improved pharmacokinetics and tolerability. The company aims to meet significant unmet needs in oncology through its proprietary cell-free protein synthesis platform.